Richard Frank on Muck Rack

Richard Frank

Roslindale
As seen in: Bloomberg Opinion, Color Research & Application, Nature, Wiley Online Library, Cambridge University Press & Assessment, Harvard Health Publishing, Fast Company, Scientific American, The Conversation, The Hill and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Richard

Contact Richard, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Medicaid Cuts Kick Down on People Caught in the Opioid Epidemic

|
By Richard Frank
| Scientific American Verified
The tragic opioid epidemic continues to rage in the U.S. Roughly 76 percent of U.S. drug overdose deaths, more than 70,000 people in 2023, are linked to opioids, including heroin and illicit fentanyl. The bill for that calamity—dire enough to justify a global trade war with Canada, Mexico and China—is falling increasingly on a federal health coverage program that now faces the chopping block.
Open in Who Shared Issue with article?

Assessing the Effect of the Medicare Part D Redesign

|
By Rachel Sachs, Richard Frank, Brookings Institution
| JAMA: Journal of the American Medical Association Verified
Assessing the Effect of the Medicare Part D Redesign Since the creation of Medicare Part D in 2003, policymakers and experts have expressed concern about the design of its benefit structure, focusing on the significant costs incurred by many beneficiaries and the ways its payment structure limited Part D plans’ incentives to lower costs.
Open in Who Shared Issue with article?

Richard Frank's Response to Commentary on Government Support of Innovation

|
By Richard Frank
| Brookings Institution
It is disappointing when scholars from reputable academic institutions enter a fact-free zone to make policy arguments. Sadly, this is exactly the line of argument that Gowda and Miller have recently pursued. They accuse the Biden-Harris administration of having “both stifled innovation and made it harder for drugs to reach patients.” I believe that it is worth looking beyond the tired pharma talking points and made-up simulation numbers to what is happening on the ground.
Open in Who Shared Issue with article?
See all 149 licensed articles (156 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified